Sonus explodiert - kein Push!!!!!!!! - 500 Beiträge pro Seite

[armerstudent]

COMBINED REAL-TIME ORDER BOOK

Bid Orders
Price Order Size Institution
6.60 100 Island
6.12 500 Island
6.00 1000 Archipelago
6.00 1000 Island
5.73 2500 Island
5.65 500 Archipelago
5.61 3000 Archipelago
5.58 4500 Archipelago
5.58 4500 Island
5.50 3000 Island
5.28 200 Island

Ask Orders
Price Order Size Institution
6.82 900 Island
6.89 200 Island
7.00 1000 Archipelago
7.35 2000 Archipelago
7.45 800 Island
7.50 1000 Archipelago


Press Release Source: Sonus Pharmaceuticals, Inc.


Sonus Pharmaceuticals Receives FDA Fast Track Designation for TOCOSOL Paclitaxel in Bladder Cancer Indication
Wednesday October 29, 7:30 am ET


BOTHELL, Wash.--(BUSINESS WIRE)--Oct. 29, 2003--Sonus Pharmaceuticals, Inc. (Nasdaq:SNUS - News) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for TOCOSOL(TM) Paclitaxel for the treatment of metastatic or locally advanced, inoperable transitional cell carcinoma (TCC) of the urothelium. The most common form of urothelial TCC is bladder cancer.
Under the FDA Modernization Act of 1997, the Fast Track program is designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. In addition to the Fast Track designation, the FDA will also accept portions of a New Drug Application (NDA) that support the TCC indication as they are completed, which is known as a "rolling NDA."

"The FDA`s Fast Track designation of TOCOSOL Paclitaxel for the treatment of patients with bladder cancer recognizes the potential of our drug to treat a serious disease for which no chemotherapeutic agent is currently approved," said Michael A. Martino, Sonus Pharmaceuticals President and CEO. "Additionally, this designation further supports our mission to secure FDA approval for TOCOSOL Paclitaxel as quickly as possible."

Sonus has completed patient enrollment in three Phase 2a studies using TOCOSOL Paclitaxel for the treatment of bladder, ovarian and non-small cell lung cancers. Based on encouraging clinical results to date, the Company is preparing to initiate new clinical studies of TOCOSOL Paclitaxel to provide data that would be the basis for regulatory approval of the product. Concurrent with the plan to pursue product approval for the treatment of bladder cancer, Sonus will also seek approval of TOCOSOL Paclitaxel for other indications through a separate development program comparing the product to Taxol® (the currently marketed paclitaxel product), leading to a 505(b)(2) NDA.

About TOCOSOL Paclitaxel

TOCOSOL Paclitaxel is a novel reformulation of paclitaxel, one of the world`s most widely prescribed anti-cancer drugs. TOCOSOL Paclitaxel, a ready-to-use formulation, does not require reconstitution, dilution or preparation as with the currently marketed paclitaxel products and other paclitaxel formulations under development. In clinical studies to date, TOCOSOL Paclitaxel is demonstrating favorable anti-tumor activity in cancer patients who have failed prior chemotherapeutic regimens. The product is also showing excellent tolerability over multiple treatment cycles, and as a result, most patients do not need to have doses reduced or delayed. TOCOSOL Paclitaxel is administered to patients in a short 15-minute infusion, compared to the prolonged three-hour infusion required with available paclitaxel products.

About Sonus Pharmaceuticals

Sonus is developing a number of potential product candidates for the treatment of cancer and other serious diseases utilizing its proprietary TOCOSOL(TM) drug delivery technology. The development of therapeutic drugs with the TOCOSOL technology may result in products that can be delivered more safely and effectively. The Company`s news releases and other information are available on the Sonus web site at www.sonuspharma.com.

Certain statements made in this press release are forward-looking such as those, among others, relating to the development of drug delivery products and potential applications for these products. As discussed in Sonus Pharmaceuticals` filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K filed on March 10, 2003, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: the Company`s products will require extensive clinical testing and approval by regulatory authorities; such approvals are lengthy and expensive and may never occur; risks that clinical studies with TOCOSOL Paclitaxel will not be successful or demonstrate increased efficacy; risks of successful development of additional drug delivery products.

Taxol® is a registered trademark of Bristol-Myers Squibb Company.



--------------------------------------------------------------------------------
Contact:
Sonus Pharmaceuticals, Inc.
Pamela L. Dull, 425-487-9500



--------------------------------------------------------------------------------
Source: Sonus Pharmaceuticals, Inc.

[armerstudent]

Am 05. November erden Quartalszahlen veröffentlicht, am 14. November Biotech-Präsentation des Medikaments!!!

Bid Orders
Price Order Size Institution
6.71 100 Island
6.52 3000 Island
6.50 2000 Island
6.31 2000 Island
6.12 500 Island
6.00 1000 Archipelago
6.00 1000 Island
5.74 4000 Island
5.73 2500 Island
5.65 500 Archipelago
5.61 3000 Archipelago

Ask Orders
Price Order Size Institution
6.97 400 Archipelago
7.30 2000 Island
7.35 2000 Archipelago
7.35 1000 Island
7.50 3200 Archipelago
7.60 300 Archipelago
7.80 1000 Archipelago
7.98 1000 Archipelago
7.98 500 Island
8.00 2600 Archipelago
8.50 500 Archipelago
15.00 200 Archipelago
15.00 200 Island

[armerstudent]

Kursziel ist übrigens $ 18!!!

[armerstudent]

Reuters
Sonus to Get Quick Review of Cancer Drug
Wednesday October 29, 7:42 am ET


NEW YORK (Reuters) - Sonus Pharmaceuticals Inc. (NasdaqNM:SNUS - News) said on Wednesday U.S. regulators would accelerate their review of the company`s experimental cancer drug, a more convenient version of the widely used treatment Taxol.
Sonus is testing its version of the drug for a range of cancers. The U.S. Food and Drug Administration (News - Websites) granted the "fast-track" review for a category of cancers that includes bladder cancer.

Fast-track review allows the agency to start reviewing data from clinical trials of a drug before the entire marketing application is complete.

[boerse-bild]

Reuters
Sonus Rises, NetEase Falls in Pre-Trade
Wednesday October 29, 8:28 am ET


CHICAGO (Reuters) - Shares of Sonus Pharmaceuticals Inc. (NasdaqNM:SNUS - News) rose in trading before the bell on Wednesday after the company said U.S. regulators would accelerate their review of its experimental cancer drug, a more convenient version of the widely used treatment Taxol.
Sonus shares moved up to $6.70 on the Instinet electronic brokerage system from Tuesday`s Nasdaq close of $5.24.

Shares of Millennium Pharmaceuticals (NasdaqNM:MLNM - News) dipped in trading on Wednesday after Germany`s Bayer AG (XETRA:BAYG.DE - News) said it had sold its stake in the U.S. biotech firm for more than $300 million and would use the proceeds to reduce debt.

Millennium shares fell to $15.85 on Instinet from Tuesday`s Nasdaq close of $16.50.

Shares of Chinese Internet media firm NetEase.com Inc. (NasdaqNM:NTES - News) fell sharply in trading before the bell on Wednesday one day after it posted a record quarterly profit. But its shares slumped as analysts said a clampdown on pornographic downloads was hurting its mobile service revenues.

Revenues for mobile services such as computer-to-phone text messages and downloads of ring tones and pictures fell 21 percent in the third quarter versus the second.

NetEase shares tumbled to $54.00 on Instinet from Tuesday`s Nasdaq close of $65.84.

Shares of Gilead Sciences Inc. (NasdaqNM:GILD - News) fell before Wednesday`s opening bell, a day after the biotech company reported higher earnings but posted sales of its HIV drug Viread that failed to meet Wall Street expectations.

Gilead shares fell to $51 on Instinet, down from their close of $59.46. On Tuesday, Gilead said quarterly earnings more than tripled on higher demand for Viread but sales in the quarter fell from the previous one, which Gilead attributed to a drop in wholesale inventories.


Ich bin dabei!!!!
Lächerliche Marktkapitalisierung bei dem Potential!
Ende des Jahres steht sie bei 10 Dollar - leider ist dann der Dollar nur noch die Hälfte wert !


Last Trade: 5.24
Trade Time: 3:55PM ET
Change: 0.00 (0.00%)
Prev Close: 5.24
Open: N/A
Bid: 6.35 x 100
Ask: 5.29 x 1000
1y Target Est: 18.00

Day`s Range: N/A - N/A
52wk Range: 1.25 - 6.45
Volume: 239,695
Avg Vol (3m): 81,681
Market Cap: 92.64M
P/E (ttm): N/A
EPS (ttm): -0.81
Div & Yield: N/A (N/A)

[boerse-bild]

Dow Jones Business News
Sonus Pharma`s Tocosol Gets FDA Fast-Track Status
Wednesday October 29, 9:38 am ET


BOTHELL, Wash. (Dow Jones)--Sonus Pharmaceuticals Inc. received fast- track status from the U.S. Food and Drug Administration (News - Websites) for Tocosol paclitaxel, its drug for the treatment of some types of inoperable transitional cell carcinoma, including bladder cancer.
ADVERTISEMENT


In a press release Wednesday, the drug maker said no chemotherapeutic agent is currently approved for urothelial transitional cell carcinoma.

Based on promising preliminary results from Phase II studies of Tocosol`s efficacy in treating bladder, ovarian and non-small cell lung cancers, Sonus is planning a new trial that would be the basis for FDA regulatory review of the drug as a bladder cancer treatment.

At the same time, the company plans to seek approval for other indications by launching other studies that compare Tocosol to the currently marketed paclitaxel drug, Taxol.

A Sonus spokeswoman wasn`t immediately available to comment on the expected timing of the planned studies or ultimate FDA review.

Sonus shares recently switched hands in premarket trading at $6.10 a share, according to Island ECN (News - Websites) , up 16% from Tuesday`s Nasdaq close of $5.24 a share.

Company Web site: http://www.sonuspharma.com

-Andrew Wallmeyer; Dow Jones Newswires; 201-938-5400

[armerstudent]

Habe ich schon mal in einem anderen Thread gepostet!

Auf der Seite von Yahoo!Finance habe ich folgendes gefunden!




well well
by: wwatt69 10/09/03 04:28 pm
Msg: 2960 of 2965

Just got off the phone with Pam, she sounds very nice.

We have set up a call for tomorrow morning at 9:30, and the CEO will be sitting in as well... Sounds a little over the top to me, but she said something about having worked out their strategy for TOCOSOL w.r.t. regulatory pathway with the FDA - maybe they are making real progress. I`m excited to hear what they have to say and will probably make sure I`m up to snuff on Multidrug Resistance Proteins....

Keep you informed.
Best


conversation
by: wwatt69 10/10/03 01:03 pm
Msg: 2963 of 2965

Hi all

Just got off the phone with Mike, he was pretty helpful and upbeat. Let me see if I can recap here, can`t promise to keep it in order...

First, he said the results coming out of the current trial continue to be very encouraging, he said they will be presenting at a Chemotherapy conference in NYC on Nov. 14th - that should be exciting. TOCOSOL Paclitaxel continues to be effective where other treatments were not, and he also said something to the effect that it was working in tumors that you wouldn`t expect taxol to work on.

I asked specifically how TOCOSOL might block MDR function - he didn`t have a direct answer, because TOCOSOL is, as it turns out, a multi-component formulation, one component of which is an alpha-tocopherol. I suspected this after doing some research last night - tocopherols have been studied as potential cancer chemotherapy, some of them are directly toxic to tumor cells, some of them seem to effect MDRs depending on which variety they are, alphsa, beta, delta... Alpha tocopherol has been described in the literature as a " membrane-stabilizing" agent, which kind of makes sense. It may inhibit the ability of MDR channels to insert into the membrane somehow. They don`t know exactly, and they don`t want to find out because the regulatory agreement they have nailed down with the FDA does not require Sonus to determine the toxicity or function of any of the individual components of TOCOSOL, just the vehicle as a whole. Mike pointed out, however, that in the early trials in melanoma xenografts which were then biopsied and analyzed for drug retention, TOCOSOL Paclitaxel produced 2-fold higher uptake/retention of the drug in tumors compared to Paclitaxel alone. Uptake/retention in all other, normal tissues was exactly the same among the two, which is a strong suggestion that there is something about TOCOSOL function that keeps it in tumor cells specifically, which implicates MDR blockage.

The regulatory route they are taking is 5052b. I do not know this nomenclature, perhaps someone here could edify us, but Mike said that will shorten the route to nda submission/approval by 2 years.

I told him my concerns about increasing blood brain barrier permeability vis-a-vis the Camptothecin application, he reminded me that in all tissues other than tumor, TOCOSOL Paclitaxel had the same absorption as Paclitaxel alone, indicating no increase in permeability. He also said that they are not going balls to the wall with Camptothecin at this point because they don`t want to run out of money.

I think that`s about it - he was quite convincing, and seemed excited about the emerging trial results, and of course said that the next couple of months should be exciting.

If I remember anything else I`ll post. Hope this is helpful, I`m encouraged.
Best...

[boerse-bild]

Heute nach Börsenschluss kommen die Zahlen!
Des weiteren sollte am 14. November 2003 eine "gute" Nachricht bei der Biotech-Konferenz veröffentlicht werden - vielleicht ein Partner!?
Dann explodiert der Kurs wirklich...

[armerstudent]

Verlust 15 Cent je Aktie!
Erwartet wurden 18 Cent je Aktie!

[crfs]

Habe die Aktie ebenfalls im Depot, aber der Tag heute gefällt mir nicht!
Wenn jemand Aktien verkauft hat, waren es immer große Packete - Insider wegen der kommenden Tage (14.Nov.)!?
Ma wes es net!

[crfs]

Allerdings muss man auch sagen, dass sie jetzt "halt" das Gap geschlossen hat - zum zweiten Mal!

[crfs]

Und auf ihrem Primärtrend ist sie nun ebenfalls gelandet!

[armerstudent]

Ich verstehe es nicht!
Die Ergebnisse sind doch nicht schlecht, oder!?
Im 2-jährigen Chart sieht man wie wichtig die 5 USD - Marke ist - da geht nichts rauf und auch nichts runter...

[armerstudent]

11. Dezember 2003:
RedChip Investor Conference Scottsdale, Arizona

[armerstudent]

Schaut Euch mal den folgenden Link an:

http://www.hoovers.com/free/co/fin/valuengine.xhtml?COID=445…

[armerstudent]

Das sieht ja heute richtig gut aus!

Hier die kommende Veranstaltung:
The Seidler Companies Life Science Conference 2004 The Palace Hotel, San Francisco January 16, 2004
Des weiteren soll ja noch im 1. Quartal 2004 ein Partner präsentiert werden, so zumindest Michael A. Martino bei der RedChip Investor Conference Scottsdale, Arizona am 11. Dezember 2003!
Go SNUS!

[boerse-bild]

bei finance.yahoo entdeckt:

traders are back; where`s the partner
by: stockspec57 (41/M/Memphis, TN) 01/08/04 02:50 pm
Msg: 3178 of 3178

still holding a core position from back in 2002, so seeing the stock run with the other low priced biotech, pharma stocks (e.g., INCY, ENCY, GENR) is nice, but without a news realese, it`s likely to fall as it has in the past. Be careful traders, SNUS doesn`t have any big national or regional sell side analyst coverage. But note that SAC Capital hasn`t sold a single share, and this is the best hedge fund out there.

[boerse-bild]

Na bitte - hier der Grund für den Anstieg der letzten 2 Tage und es scheint keine Gewinnmitnahmen zu geben!!!
Vielleicht wissen ein paar Menschen mehr als andere - Partner!?
Kursziel (18 Dollar) wir kommen...



Press Release Source: Sonus Pharmaceuticals, Inc.


Sonus Pharmaceuticals Continues to Expand Patent Estate for TOCOSOL Paclitaxel Anti-Cancer Drug
Friday January 9, 7:41 am ET


BOTHELL, Wash.--(BUSINESS WIRE)--Jan. 9, 2004--Sonus Pharmaceuticals, Inc. (Nasdaq:SNUS - News) today announced that it has been awarded a third United States patent, No. 6,667,048, covering the composition of TOCOSOL(TM) Paclitaxel, the Company`s lead cancer product. Paclitaxel, the active ingredient in TOCOSOL Paclitaxel, is a member of the taxane class of chemotherapeutic agents, one of the most widely prescribed anti-cancer drugs on the market today.
"This patent further strengthens our intellectual property estate for TOCOSOL Paclitaxel, which we believe will be an important compound in the next generation of taxane-based cancer fighting products," said Michael A. Martino, President and CEO of Sonus Pharmaceuticals. "TOCOSOL Paclitaxel, the first application of our proprietary TOCOSOL(TM) drug delivery technology, may offer a number of potential advantages over the currently marketed taxane products, including more convenient administration, better tolerability as well as improved safety and efficacy."

About TOCOSOL Paclitaxel

TOCOSOL Paclitaxel is an injectable, ready-to-use formulation of paclitaxel. The product does not require reconstitution, dilution or preparation as is required with the currently marketed paclitaxel products. In clinical trials to date, TOCOSOL Paclitaxel has demonstrated promising anti-tumor activity in cancer patients who have failed prior chemotherapeutic regimens. The product is well tolerated when given in a short 15-minute infusion compared to the prolonged three-hour infusion required with the marketed paclitaxel products. The Company has completed patient enrollment in the Phase 2a clinical program for TOCOSOL Paclitaxel, and is initiating the next round of clinical studies to provide data that will be the basis for registration with U.S. and international regulatory authorities.

About Sonus Pharmaceuticals

Sonus is currently developing a number of potential product candidates for the treatment of cancer utilizing its proprietary TOCOSOL drug delivery technology. The development of therapeutic drugs with the TOCOSOL technology may result in products that can be delivered more safely and effectively. The Company`s news releases and other information are available on the Sonus web site at www.sonuspharma.com.

Certain statements made in this press release are forward-looking such as those, among others, relating to the development, safety and efficacy of drug delivery products and potential applications for these products. As discussed in Sonus Pharmaceuticals` filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K filed on March 10, 2003, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: the Company`s products will require extensive clinical testing and approval by regulatory authorities; such approvals are lengthy and expensive and may never occur; risks that clinical studies with TOCOSOL Paclitaxel will not be successful or demonstrate increased efficacy; risks of successful development of additional drug delivery products; risks that any patents issued to the Company will survive Patent Office or legal challenges or will be ultimately enforceable; risks that third parties will be able to develop products or processes that do not infringe any valid patents held by Sonus; and risks that any patents will issue from the Company`s pending or future patent applications.



--------------------------------------------------------------------------------
Contact:
Sonus Pharmaceuticals, Inc.
Pamela L. Dull, 425-487-9500

[armerstudent]

Das sieht gut aus!
Charttechnisch müßte es in den Bereich von $ 8 gehen...
Je schneller es geht, desto besser - denn wenn SNUS erneut ein Plateau im Bereich von $ 6,50 - $ 7,00 entwickelt, kann es wieder Monate dauern, trotz guter Nachrichten bis dieses genommen wird!
Ich bin zwar jung, aber so lange will ich dann doch nicht warten ;-)

[armerstudent]

Jetzt gebe ich mein Studium auf und werde Charttechniker ...

Hier noch ein Posting aus finance.yahoo.com:

Re: wake up folks
by: gogetem75 (M/Tucson, AZ)
Long-Term Sentiment: Strong Buy 01/22/04 08:06 pm
Msg: 3188 of 3191

yep, every day that goes by is one day closer to a partner signing. In addition keep in mind
--the three 2b clinical trials that kicked off in November 2003
--the slew of patent filings 2 years ago whose obtention will trigger over the course of 2004
--the promised news about Campothecin and other pipeline ai`s now in tocosol development.
Good news will be trickling out all through the next 12 months, making for steady share price increases.
SNUS is a jewel that has yet to be discovered by the retail market; very similar to FLML before it went from 2 to 35 last year.

[armerstudent]

Re: wake up folks
by: bladerunner1717
Long-Term Sentiment: Strong Buy 01/23/04 02:25 pm
Msg: 3192 of 3192

Sturza reiterated his "buy" recommendation last night with a target--one year?--of $12/share. He expects a partnership agreement in "mid-2004." He believes the pharmacokinetic study, already underway, will be important for the acceptance of the NDA by way of a 505(b)(2) submission. He believes the pharmacokinetic study will be completed in Q2,04 and that SNUS will meet with the FDA shortly thereafter.

Bladerunner



Posted as a reply to: Msg 3188 by gogetem75

[armerstudent]

Momentan findet m.E. eine normale Konsolidierung nach den Gewinnen statt! Sollten die Zahlen am 10. Februar 2004 im Rahmen der Erwartungen sein, denke ich das der Kurs erstmal zwischen $ 7,30 und $ 8,30 pendeln wird - sind die Zahlen postiv könnte das nächste Plateau auch im Bereich von $ 9,00 und $ 10,00 gebildet werden ...

[armerstudent]

Invest Northwest 2004 Webcast March 23, 2004, 11:00 A.M. PT
Bell Harbor International Conference Center
Seattle, WA

[boerse-bild]

Wer heute noch investiert - freut sich vielleicht morgen wie ein Schnitzel... Oder auch nicht! Das ist Börse! Ich denke aber, dass dieses Jahr vom heutigen Kurs mindestens noch mal 100 % drin sind

[armerstudent]

In den letzten Minuten steigt der Kurs deutlich!


Symbol: SNUS
Last Trade: 7.50 2:32PM ET
After Hours Change: N/A
Today`s Change: 0.34 (4.75%)
Bid: 7.47
Ask: 7.50


Hoffentlich setzt sich das morgen und vorallem am Mittwoch fort!!! SNUS $ 9,00 bis Ende dieser Woche

[armerstudent]

Tja, was soll ich sagen!?
Ich bin überfragt, ob die Aussagen gestern postiv oder negativ sind! Ehrlich gesagt hätte ich mir mehr erhofft!
Neueste Nachricht:

Press Release Source: Sonus Pharmaceuticals, Inc.


Sonus Pharmaceuticals Expands Drug Development Organization
Wednesday February 11, 7:30 am ET


BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 11, 2004--Sonus Pharmaceuticals, Inc. (Nasdaq:SNUS - News) today announced that it has broadened and deepened its research and corporate development capabilities with the appointments of Lynn Gold, Ph.D. as Vice President of Research and Process Development, and Neile Grayson, Ph.D. as Vice President of Strategic Planning and Corporate Development. In addition, Sonus veteran Dean Kessler has been promoted to Vice President of Preclinical Development to round out the non-clinical research and development management team with Lynn Gold. This leadership, coupled with the Company`s clinical and regulatory expertise, enhances Sonus` ability to coordinate and integrate all activities required to discover, manufacture, develop and commercialize new medicines.
ADVERTISEMENT


"This investment to further strengthen our organization comes at a time when we are making excellent progress to bring our lead cancer product, TOCOSOL(TM) Paclitaxel, to market," said Michael A. Martino, President and CEO of Sonus Pharmaceuticals. "We believe that there are significant opportunities ahead to apply our technology to new and innovative drugs and bring additional products into clinical development. With a strong management team already in place, augmented by these additional capabilities, we are well positioned to expand our base as a pharmaceutical development company."

Lynn Gold has extensive experience with pharmaceutical development, specifically with the application of emulsion formulations, a major component of Sonus` core technology platform. In her new position, Dr. Gold will oversee discovery research, formulation development, analytical chemistry, manufacturing and quality control at Sonus. Her previous experience includes 13 years at Fresenius Kabi where she had operating responsibility for product development as well as business development activities.

Neile Grayson has breadth and depth of experience in the development of new drugs, from discovery to the clinic, to structuring and managing external collaborations. Dr. Grayson joins Sonus from NeoRx Corporation in Seattle where she served as Vice President of Corporate Development. Her past experience also includes nine years at Mallinckrodt where she directed activities related to identifying and assessing corporate growth opportunities. In her new role at Sonus, Dr. Grayson will provide strategic insights in the selection of research and development projects and will identify and market the Company`s technology and products to prospective commercial partners.

Dean Kessler has more than 16 years experience in the preclinical evaluation of new pharmaceuticals. He joined Sonus in 1992 as a Research Scientist, and, during his tenure, has made key contributions to the development of TOCOSOL Paclitaxel and earlier-stage products, and the scope and magnitude of his responsibilities have steadily increased. As Vice President of Preclinical Development, Mr. Kessler will have responsibility for all aspects of biological screens, experimental non-clinical pharmacology and non-clinical safety assessments for new products.

About Sonus Pharmaceuticals

The Company`s lead product is TOCOSOL Paclitaxel, a cancer therapeutic formulated with Sonus` proprietary TOCOSOL drug delivery technology. TOCOSOL Paclitaxel is an injectable, ready-to-use formulation of paclitaxel, one of the world`s most widely prescribed anti-cancer drugs. In clinical trials to date, TOCOSOL Paclitaxel has demonstrated promising anti-tumor activity in multiple tumor types. The product is well tolerated and is given in a short 15-minute infusion compared to the prolonged three-hour infusion required with the marketed paclitaxel products. The Company has completed patient enrollment in the Phase 2a clinical program for TOCOSOL Paclitaxel, and has initiated the next round of clinical studies to provide data that will be the basis for registration with U.S. and other national regulatory authorities.

Sonus news releases and other information are available at www.sonuspharma.com.

Certain statements made in this press release are forward-looking such as those, among others, relating to the development, safety and efficacy of drug delivery products and potential applications for these products. As discussed in Sonus Pharmaceuticals` filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K filed on March 10, 2003, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: the Company`s products will require extensive clinical testing and approval by regulatory authorities; such approvals are lengthy and expensive and may never occur; risks that clinical studies with TOCOSOL Paclitaxel will not be successful or demonstrate increased efficacy; and risks of successful development of additional drug delivery products.



--------------------------------------------------------------------------------
Contact:
Sonus Pharmaceuticals, Inc.
Pamela L. Dull, 425-487-9500



--------------------------------------------------------------------------------
Source: Sonus Pharmaceuticals, Inc.

[armerstudent]

Sonus Pharmaceuticals Highlights 2003 Strategic Accomplishments and Reports Fourth Quarter and Annual Financial Results
Tuesday February 10, 4:03 pm ET


BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 10, 2004--Sonus Pharmaceuticals, Inc. (Nasdaq:SNUS - News) today reported 2003 strategic accomplishments and fourth quarter and annual financial results.
"2003 was another strong and productive year for Sonus. We achieved a number of specific objectives to advance TOCOSOL(TM) Paclitaxel, our lead cancer drug," said Michael A. Martino, Sonus Pharmaceuticals President and CEO. "As a result, we enter 2004 with clarity and momentum in our efforts to accelerate the clinical and regulatory development of this product."

2003 Strategic Accomplishments:

Completed patient enrollment in Phase 2a clinical program for TOCOSOL Paclitaxel. In clinical studies to date, the product has been well tolerated and is demonstrating promising safety and anti-tumor activity in multiple tumor types, including lung, ovarian and bladder cancers.
Developed versatile regulatory strategy for TOCOSOL Paclitaxel and initiated two new clinical studies in the implementation of that strategy. The Company`s goal is to submit the initial New Drug Application for TOCOSOL Paclitaxel under its 505(b)(2) program in late 2005 or early 2006.
Received Fast Track designation from the U.S. Food and Drug Administration for development of TOCOSOL Paclitaxel for the treatment of inoperable or metastatic transitional cell carcinomas of the urothelium, most of which are bladder cancers. This designation recognizes the potential of TOCOSOL Paclitaxel to treat a serious disease for which no chemotherapeutic agent is currently approved.
Scaled manufacturing process for TOCOSOL Paclitaxel to ensure adequate clinical supply for ongoing and planned trials, and to provide a commercial scale process to enable regulatory approval.
Strengthened intellectual property position with the issuance of two new patents for TOCOSOL Paclitaxel. Sonus was issued an additional patent related to its TOCOSOL technology platform in late January 2004. The Company now has a total of five issued patents in the United States, with three of those specific to TOCOSOL Paclitaxel.
Expanded clinical and regulatory development capabilities, including the additions of Michael B. Stewart, M.D. as Senior Vice President and Chief Medical Officer, and Elaine Waller, Pharm.D. as Vice President of Regulatory Affairs and Quality Assurance.
Enhanced cash position with completion of private equity financing that raised $13.1 million in net proceeds.
2003 Financial Results:

For the fourth quarter of 2003, Sonus reported a net loss of $2.6 million, or $0.15 per share, compared with a net loss of $2.4 million, or $0.18 per share, in the fourth quarter of 2002. For the year ended December 31, 2003, the Company reported a net loss of $10.5 million, or $0.68 per share, compared with a net loss of $11.6 million, or $0.86 per share, in the prior year period.

The lower net loss in 2003 was due primarily to the completion of patient enrollment in the Phase 2a clinical program for TOCOSOL Paclitaxel in mid-2003. These Phase 2a studies were initiated in early 2002. Sonus anticipates that its level of spending will increase in 2004 to support additional clinical studies in the implementation of the regulatory approval strategy for TOCOSOL Paclitaxel as well as new product development activities. The forecasted net cash burn for 2004 is approximately $1.0 to $1.5 million per month, with actual spending within this range dependent on the timing of clinical and research activities. Cash and marketable securities totaled $19.7 million at December 31, 2003.

About Sonus Pharmaceuticals

The Company`s lead product is TOCOSOL Paclitaxel, a cancer therapeutic formulated with Sonus` proprietary TOCOSOL drug delivery technology. TOCOSOL Paclitaxel is an injectable, ready-to-use formulation of paclitaxel, one of the world`s most widely prescribed anti-cancer drugs. Sonus has completed patient enrollment in Phase 2a clinical studies of TOCOSOL Paclitaxel, and has initiated the next round of clinical trials to provide data that will be the basis for registration with U.S. and other national regulatory authorities. Sonus news releases and other information are available on the Company`s web site at www.sonuspharma.com.

Quarterly Conference Call Information:

Sonus will provide a company update during its quarterly conference call today, February 10, 2004, at 1:30 P.M. Pacific Time/4:30 P.M. Eastern Time. The call will be web cast live and archived on Sonus` web site at www.sonuspharma.com/events.html. A replay of the conference call will also be available via telephone for one week at [phone] or [phone] for international calls; Pass code 5187939.

Certain statements made in this press release are forward-looking such as those, among others, relating to the development, safety and efficacy of drug delivery products and potential applications for these products and the anticipated filing date of regulatory approval. As discussed in Sonus Pharmaceuticals` filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K filed on March 10, 2003, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: the Company`s products will require extensive clinical testing and approval by regulatory authorities; such approvals are lengthy and expensive and may never occur; and risks that clinical studies with TOCOSOL Paclitaxel will not be successful or demonstrate increased efficacy.

Condensed Statements of Operations
(in thousands, except per share amounts)


Three Months Twelve Months
Ended Ended
December 31, December 31,
----------------- -------------------
2003 2002 2003 2002
------- ------- -------- --------

Revenue $ - $ - $ 25 $ 25
Operating expenses:
Research and development 1,876 1,855 7,653 8,957
General and administrative 771 730 3,010 3,242
------- ------- -------- --------
Total operating expenses 2,647 2,585 10,663 12,199
------- ------- -------- --------
Operating loss (2,647) (2,585) (10,638) (12,174)
Interest income, net 41 75 171 437
------- ------- -------- --------
Loss before income taxes (2,606) (2,510) (10,467) (11,737)
Income tax benefit - 101 - 101
------- ------- -------- --------
Net loss $(2,606) $(2,409) $(10,467) $(11,636)
======= ======= ======== ========

Net loss per share:
Basic $ (0.15) $ (0.18) $ (0.68) $ (0.86)
Diluted $ (0.15) $ (0.18) $ (0.68) $ (0.86)

Shares used in calculation:
Basic 17,911 13,679 15,504 13,564
Diluted 17,911 13,679 15,504 13,564



Condensed Balance Sheets
(in thousands)

December 31, December 31,
2003 2002
------------- ------------

Assets:
Cash and marketable securities $ 19,664 $ 16,334
Other current assets 198 290
Property and equipment, net 1,606 1,310
------------- ------------
Total assets $ 21,468 $ 17,934
============= ============
Liabilities and stockholders` equity:
Accounts payable and accrued expenses $ 1,886 $ 1,801
Lease obligations 272 409
Stockholders` equity 19,310 15,724
------------- ------------
Total liabilities and stockholders`
equity $ 21,468 $ 17,934
============= ============



--------------------------------------------------------------------------------
Contact:
Sonus Pharmaceuticals
Pamela L. Dull or Richard J. Klein, 425-487-9500



--------------------------------------------------------------------------------
Source: Sonus Pharmaceuticals

[boerse-bild]

Kursziel ist wieder bei 18 Dollar...

[boerse-bild]

Vielleicht deshalb...

Sturza reiterated Strong Buy on SNUS
by: gogetem75 (M/Tucson, AZ)
Long-Term Sentiment: Strong Buy 02/13/04 01:47 pm
Msg: 3224 of 3224

last night

[armerstudent]

Invest Northwest 2004 Webcast March 23, 2004, 11:00 A.M. PT
Bell Harbor International Conference Center
Seattle, WA

Bei dieser Veranstaltung werden die konkreten Ergebnisse der Phase 2 bekanntgegeben!
Spekulation im Vorfeld oder wissen manche mehr als andere!?
Heute jedenfalls sind die 8 Dollar innerhalb von Minuten genommen worden - ohne Grund!!!
PZK hält weiterhin das "Strong Buy" mit Kursziel 18 Dollar - und kein Externer kennt die Firma besser!!!
SNUS goooooooooo!!!

[armerstudent]

Wahnsinn - was ist jetzt passiert!?
Real-Time kennt die Aktie keinen Halt!
9 DOLLAR !!!!!
SNUS GOOOOOOOOOOOOOOOOOOO!!!!!!!!!!!

[boerse-bild]

Tja, was hat das zu bedeuten!?
Ich weis es leider nicht...

19-Feb-04 SAC CAPITAL ASSOCIATES LLC
Beneficial Owner (10% or more) 185,000 Sale at $8.50 - $8.662 per share. $1,587,0002
19-Feb-04 COHEN, STEVEN A/SAC CAPITAL MGMT LP
Beneficial Owner (10% or more) 185,000 Sale at $8.50 - $8.662 per share. $1,587,0002
19-Feb-04 SAC CAPITAL ADVISORS LLC
Beneficial Owner (10% or more) 185,000 Sale at $8.50 - $8.662 per share. $1,587,0002
19-Feb-04 S A C CAPITAL MANAGEMENT L L C
Beneficial Owner (10% or more) 185,000 Sale at $8.50 - $8.662 per share. $1,587,0002

[armerstudent]

Bin gestern ebenfalls zu $7,50 raus!!!
Die Insiderverkäufe vor Veröffentlichung der Testergebnisse am 23. März 2004 machen mich stuzig!
Bin jetzt in einem Nanowert namens MFIC.OB - dort kaufen Insider große Mengen in den letzten Wochen ein...

[boerse-bild]

MFIC sieht nicht schlecht aus - vorallem wegen der INSIDERKÄUFE... Werde mir auch ein paar zulegen!